White Paper

Product Alert - Lumateperone Tosylate

Lumateperone is a serotonin 5HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), and a serotonin transporter (SERT) inhibitor. Unlike existing schizophrenia treatments, Lumateperone is a first-in-class molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate—three neurotransmitter pathways implicated in severe mental illness.

Our Offerings*:

• We offer the crystalline form-A*
• Early mover in API development and filed USDMF. Planning to file the DMF in key markets such as China, Japan, Brazil, Europe, and Korea.
• Current batch size of 10-15 kg. Adequate capacity available to supply development quantity in a short lead time of 90-120 days.
• cGMP API manufacturing facilities, successfully inspected by international regulatory authorities.

To learn more about our API offerings, please read the Product alert on Lumateperone by filling out the contact form below.